SUBSCRIBERS

CCCS invites feedback over merger concerns on PAH deals

Response will help watchdog assess if planned consolidation of two clinical laboratories will reduce competition

Fiona Lam

Published Fri, Jun 21, 2019 · 09:50 PM

Singapore

THE Competition and Consumer Commission of Singapore (CCCS) is inviting public feedback on the two-year commitments proposed by Pathology Asia Holdings (PAH) to address competition concerns in its planned merger of two private clinical laboratories.

PAH, a unit of private equity giant TPG Capital Asia, intends to integrate the businesses of the two labs - Innovative Diagnostics and Quest Laboratories - after acquiring them last year.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes